Long term follow up of topical mustine treatment for cutaneous Langerhans cell histiocytosis
Authors:
- Peter H HoegerPHPeter H Hoeger
- Vasanta R NanduriVNVasanta R Nanduri
- Jon PritchardJPJon Pritchard
Open Access
- 1 June 2000
- journal article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 82 (6) , 483-487
Abstract
BACKGROUND AND OBJECTIVES Skin lesions in Langerhans cell histiocytosis (LCH) are often painful and difficult to treat. Topical application of nitrogen mustard (0.02% mechlorethamine hydrochloride, mustine), an alkylating cytostatic agent, has been shown to be effective. There is, however, concern about potentially harmful long term side effects. STUDY DESIGN In a retrospective study 20 children with LCH (average extent of initial skin involvement: 16.4% body surface) were followed up for an average of 8.3 years after completion of topical mustine therapy. They had received a total of 34 courses (mean duration 14.2 weeks) of topical mustine. Disease status on follow up was assessed according to the Histiocyte Society classification. RESULTS After mustine was introduced, 16 patients were able to discontinue systemic steroids and/or chemotherapy. Topical mustine was well tolerated in 18 patients, but two developed irritant dermatitis. On follow up, the disease was inactive in 10 patients. Among the children with active disease, six had mild skin disease and four had progressive disease, two of them with skin lesions unresponsive to mustine treatment. Scars confined to areas of formerly active skin disease were found in six patients. There was no evidence of premalignant or malignant skin disease in the treated areas. CONCLUSION Topical mustine is an effective and safe treatment for skin disease in most children with LCH. Residual scarring was probably a result of the disease itself rather than to mustine. Although no evidence of skin cancer was found in this study, continued long term follow up is advisable.Keywords
This publication has 31 references indexed in Scilit:
- Langerhans cell histiocytosisThe Journal of Pediatrics, 1995
- Topical nitrogen mustard: An effective treatment for cutaneous Langerhans cell histiocytosisThe Journal of Pediatrics, 1991
- Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphomaJournal of the American Academy of Dermatology, 1989
- No detectable increase in sister chromatid exchanges in lymphocytes from mycosis fungoides patients after topical treatment with nitrogen mustardBritish Journal of Dermatology, 1988
- Cutaneous malignancies and metastatic squamous cell carcinoma following topical therapies for mycosis fungoidesJournal of the American Academy of Dermatology, 1986
- Histiocytosis X: A seven-year experience at a children's hospitalJournal of the American Academy of Dermatology, 1985
- Skin cancer in psoriatics treated with nitrogen mustardJournal of the American Academy of Dermatology, 1983
- Cancer in patients with psoriasisJournal of the American Academy of Dermatology, 1982
- Second cutaneous malignancies in patients with mycosis fungoides treated with topical nitrogen mustardJournal of the American Academy of Dermatology, 1982
- Histiocytosis X in two infants—treated with topical nitrogen mustardBritish Journal of Dermatology, 1979